Nail disorders in a woman treated with ixabepilone for metastatic breast cancer.

Andrea Alimonti(Veneto Institute of Molecular Medicine), Francesco Cognetti(Apple (Israel)), Alessandra Fabi(Agostino Gemelli University Polyclinic), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), C. Nardoni(Cancer Institute (WIA)), Paola Papaldo(Cancer Institute (WIA)), Maria Pia Caleno, Debora Rasio(Azienda Ospedaliera Sant'Andrea), Paolo Carlini(National Cancer Institute)
PubMed
October 13, 2005
Cited by 9

Related Papers

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Cellular Senescence: Aging, Cancer, and Injury
|Physiological Reviews|2019|1.3k
Subtle variations in Pten dose determine cancer susceptibility
|Nature Genetics|2010|579
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy
|JAMA Oncology|2018|345
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253